CAJ | 학술논문

目的探讨硼替佐米体外对前列腺癌细胞迁移和侵袭的影响及其机制.方法选择对数生长的LNCAP前列腺癌细胞株,分别选择不同浓度的硼替佐米处理,在处理24h后进行前列腺癌细胞迁移和侵袭的检测,同时收集细胞进行炎症因子表达实验和Western blot检测分析.结果 LNCAP+硼替佐米(10nmol/L)组、LNCAP+硼替佐米(20nmol/L)组细胞的迁移指数与侵袭指数都明显低于单独LNCAP组,并且IL-12及TNF-α表达量明显低于单独LNCAP组,对比差异都有统计学意义(P＜0.05).不同浓度的硼替佐米处理LNCAP细胞24h后,FAK总蛋白无明显变化,对比差异都无统计学意义(P＞0.05).结论硼替佐米能够有效抑制前列腺癌LNCAP细胞的迁移和侵袭,其作用的发挥与抑制IL-12及TNF-α的表达分泌有关,但对FAK总蛋白的表达无影响.
목적 탐토붕체좌미체외대전렬선암세포천이화침습적영향급기궤제.방법 선택대수생장적LNCAP전렬선암세포주,분별선택불동농도적붕체좌미처리,재처리24h후진행전렬선암세포천이화침습적검측,동시수집세포진행염증인자표체실험화Western blot검측분석.결과 LNCAP+붕체좌미(10nmol/L)조、LNCAP+붕체좌미(20nmol/L)조세포적천이지수여침습지수도명현저우단독LNCAP조,병차IL-12급TNF-α표체량명현저우단독LNCAP조,대비차이도유통계학의의(P＜0.05).불동농도적붕체좌미처리LNCAP세포24h후,FAK총단백무명현변화,대비차이도무통계학의의(P＞0.05).결론 붕체좌미능구유효억제전렬선암LNCAP세포적천이화침습,기작용적발휘여억제IL-12급TNF-α적표체분비유관,단대FAK총단백적표체무영향.
Objectives To investigate the migration and invasion effects and its mechanism of bortezomib on prostate cancer cell in vitro.Methods Selected LNCAP logarithmic growth of prostate cancer cell lines,given with different levels of bortezomib treatment.After 24h,the migration and invasion of prostate cancer were detected,and we collected cells for expression of inflammatory cytokines experiments and Western blot analysis.Results The cell migration index and invasion index of the LNCAP + bortezomib (10nmol/L) group and LNCAP + bortezomib (20nmol / L) group were significantly lower than for individual LNCAP group,and the IL-12 and TNF-α expression levels were also significantly lower than single LNCAP group,compared to the differences were statistically significant(P ＜ 0.05).When given the different levels of bortezomib treatment in the LNCAP ceils after 24h,The total protein FAK changes showed no significant data(P ＞0.05).Conclusions Bortezomib can effectively inhibit the migration and invasion of prostate cancer cells,and it may inhibite the expression of IL-12 and TNF-αbut it had no effect on the expression of total FAK protein.